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ABSTRACT  
Purpose: Prognosis for relapsed/ refractory high risk Neuroblastoma (HR-NBL) 
remains poor. Bortezomib, a proteasome inhibitor has shown preclinical activity 
against NBL, as a single agent and in combination with cytotoxic chemotherapy 
including irinotecan.  
Patients and Methods: Eighteen HR-NBL patients with primary refractory (n=8) or 
relapsed (n=10) disease were enrolled in a Phase-I study using modified Time To 
Event Continuous Reassessment Method (TITE-CRM).  Bortezomib (1.2 
mg/m2/day) was administered on days 1, 4, 8 and 11 intravenously, irinotecan given 
IV on days 1-5 (35, 40, or 45 mg/m2/day, on dose levels (DL) 1-3 respectively). The 
maximum tolerated dose (MTD), dose limiting toxicity (DLT) and response rate were 
examined. 
Results: Eighteen NBL patients were evaluable for toxicity, 17 were evaluable for 
response assessment. A total of 142 courses were delivered (mean 8.2, median 2, 
range 1-48) with 2 patients receiving > 40 courses of therapy. Two dose limiting 
toxicities (DLT) were reported, including a grade-4 thrombocytopenia (DL2) and a 
grade-3 irritability (DL3). MTD was estimated as DL3. 2/17 (12%) evaluable patients 
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showed objective responses (OR) lasting > 40 courses, including 1 partial remission 
(PR), 1 complete remission (CR). Four patients (23%) had prolonged stable disease 
(SD) lasting 6 or more courses with a total of 35% study patients demonstrating 
clinical benefit in form of prolonged OR or SD.  
Conclusion The combination of bortezomib and irinotecan was well tolerated by 
patients with relapsed/ refractory NBL with favorable toxicity profile. It also showed 
modest but promising clinical activity and merits further testing in Phase-II studies.  
INTRODUCTION  
Despite recent advances in high risk Neuroblastoma (NBL) therapy, long-term survival for 
patients with metastatic or high risk disease remains less than 40%[1-3]. Further, patients 
who experience a relapse of their disease or fail to achieve complete remission have an 
extremely poor prognosis with 2-year survival rates < 25%[4-7]. Better understanding the 
biology of neuroblastoma is critical in identifying new therapeutic targets and improving 
outcomes for this patient population.  
Irinotecan is a camptothecin prodrug which induces cytotoxicity through its 
active metabolite (SN-38) by inhibiting the nuclear enzyme topoisomerase–I. It has 
shown single-agent activity against NBL in both in vivo mouse models of NBL[8-10] 
as well as in patients with refractory NBL in multiple clinical trials[11-15]. 
Bortezomib is a selective inhibitor of the ubiquitin proteasome pathway 
(UPP) which is essential for the degradation of most intracellular proteins involved in 
critical cellular processes, including cell cycle regulation, apoptosis and transcription 
factor activation[16,17]. Bortezomib selectively sensitizes malignant cells to 
apoptosis, although the precise mechanism of its anti-cancer activity is unknown 
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[18]. NF-κB is a known regulator of neuroblastoma tumor cell survival[19,20] and 
bortezomib has shown ability to decrease NF-κB activity by inhibition of I-κB 
degradation in NBL cell lines as well as other systems[21]. In addition, bortezomib 
has been shown to be synergistic with a variety of chemotherapy agents including 
irinotecan, in both in vitro and in vivo xenograft models of disease[17,22]. 
Bortezomib has already been shown to be safe in children with refractory solid 
tumors in a Phase-I study and is well tolerated[23]. In view of the potential synergy 
between irinotecan and bortezomib, we designed a phase-I clinical trial to study the 
safety, maximum tolerated dose (MTD) and clinical activity of this combination in 
patients with relapsed/ refractory high risk NBL. The traditional 3+3 design has been 
the standard for conducting pediatric phase-I clinical trials. However, it has several 
disadvantages, including intermittent suspension for toxicity evaluation between 
dose escalations. In a single institution phase-I trial for a rare disease, where an 
eligible patient can come anytime, these stoppages can lead to unnecessary delays 
and many eligible patients would not be able to participate if they present during trial 
closure. To avoid this, we deployed a novel, more adaptive, simulation model-based 
dose escalation design, known as the Time To Event Continual Reassessment 
Method (TITE-CRM)[24]. This design has been tested in adult phase-I studies and it 
has shown to be as safe as standard rolling six or 3+3 designs. Importantly, TITE-
CRM trials have the advantage of being the most efficient trial design as far as 
timely completion of trial is concerned, [25].  More recently, modified phase-I CRM 
design was also shown to be more accurate in predicting MTD, exposing fewer 
patients to potentially toxic doses in pediatric brain tumor consortium trial 
(PBTC)[26].  
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PATIENTS AND METHODS  
Eligibility  
Patients with histology proven high-risk NBL 30 years or younger at diagnosis were 
eligible if they had either recurrent/progressive disease or refractory disease after 
front-line therapy with a minimum of 4 cycles of multi-agent chemotherapy. Patients 
were required to have either measurable disease (>10mm in one dimension) on 
computed tomography (CT) or magnetic resonance imaging (MRI), or evaluable 
disease with uptake in at least 1 abnormal site by metaiodobenzylguanidine (MIBG) 
scintigraphy, with or without bone marrow (BM) involvement. However, patients 
whose only known site of disease was bone marrow involvement were not eligible 
for the study. Other eligibility criteria included Karnofsky or Lansky scores ≥ 60, 
recovery from acute toxic effects of prior therapies; negative pregnancy test for 
women of child-bearing potential; absolute neutrophil count ≥1,000/uL, platelet 
count ≥100,000/DL, and adequate renal and hepatic function as defined by serum 
creatinine ≤1.5x normal serum creatinine as adjusted for age, ALT ≤2.5x ULN for 
age, and bilirubin <1.5x ULN for age. Patients with BM involvement at study entry 
were eligible irrespective of hematologic parameters, but they were not eligible for 
evaluation for hematological toxicities. More than 3, 6 or 8 weeks must have 
elapsed from prior cytotoxic chemotherapy, high dose MIBG therapy or autologous 
stem-cell transplantation respectively. Exclusion criteria included use of enzyme-
inducing anticonvulsants, active infection, or ≥ grade 2 diarrhea (CTCv3.0). Patients 
had to complete 2 cycles of chemotherapy in order to be eligible for response 
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evaluation. Clinical protocol and informed consent documents were approved by 
local institutional review boards prior to patient enrollment.  
 
Drug Administration  
Irinotecan was administered intravenously (IV) over 60 minutes on Days 1-5. The 
starting dose of irinotecan was selected as a 35mg/m2/day, which is 70% of a single 
agent IV irinotecan MTD[15]. The study planned to examine 5 dose levels of 
irinotecan: DL 1-4 at 35, 40, 45 and 50mg/m2/day respectively, with a starting dose 
level of 35mg/m2/day and a de-escalation dose level -1 of 30mg/m2/day. No intra-
patient dose escalation was allowed. Bortezomib (1.2 mg/m2/day, IV bolus infusion) 
was administered following irinotecan on days 1, 4, 8, and 11 of each 21 day cycle, 
with dosing based upon a prior pediatric phase I trial for refractory solid tumors[23].  
Supportive care: Supportive care measures included daily oral cefixime 
(8mg/kg/day with maximum daily dose of 400mg) or cefpodoxime (10mg/kg/day 
divided BID with a maximum daily dose of 800mg), 3 days prior and 2 days following 
chemotherapy completion. Patients were given instructions for use of loperamide to 
treat diarrhea occurring >24 hours after irinotecan. Filgrastim (granulocyte colony-
stimulating factor) was only recommended to be administered during subsequent 
courses of therapy for patients who were hospitalized for fever and neutropenia or in 
whom re-initiation of prior cycles were delayed for > 14 days due to neutropenia.  
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Study Design  
Study was conducted using a modification of the Time-to-Event Continual Reassessment 
Method (TITE-CRM). The TITE-CRM assumes a regression model for the probability of DLT 
as a function of dose, and allows information from all patients enrolled in the trial to be 
employed when allocating a new patient to a dose level. Subjects were continuously 
recruited throughout the trial, without recruitment pauses. In this study, a priori DLT 
probabilities (“skeleton”) for the five doses are, in dose order: 0.05, 0.10, 0.15, 0.25, and 
0.35.  The power model (containing a single parameter β) was used to model the DLT rate of 
each dose. We placed a normal distribution with mean 0 and standard deviation 0.3 on the 
parameter β.  To incorporate patients with partial follow-up for DLT, uniformly distributed 
DLT times were assumed.  The MTD was defined as the highest dose with DLT probability 
of no more than 0.25. Furthermore, we have adopted a number of steps that limit escalation 
and obtain a safety profile. These steps include: 1) The dose assigned to each patient has 
an estimated DLT rate closest to, but not greater than the target probability; 2) Dose 
escalation is restricted to one level between adjacent patients; 3) Escalation from the current 
dose is not allowed until at least one patient assigned to the current dose completes their 
follow-up; and 4) Discontinue the trial when the probability of DLT at the lowest dose is 
larger than 25%. Details of TITE-CRM study design and simulation studies of the proposed 
design have been summarized in detail in an earlier report[24]. All dose escalation decisions 
being supervised and approved by study statistician (LZ). Patients were allowed a maximum 
of 3 years provided that that they didn’t develop disease progression, or other protocol 
related toxicity which necessitated cessation of protocol therapy.  
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Required observations included performance of a weekly history and physical exam, 
CBC with differential, comprehensive metabolic panel (including albumin, liver 
function, renal function and electrolytes) and spot urine VMA and HVA repeated at 
the beginning of each cycle. Re-evaluation was performed using CT/MRI 
chest/abdomen/pelvis, I123-MIBG scan, after cycles 2, 4, 8, and 12 and every 4 
cycles on study thereafter. Bilateral bone marrow biopsy and aspirate were obtained 
with re-evaluation if positive at study entry.  
 
Monitoring for Toxicity and Response Evaluation: Toxicities were graded 
according to Common Toxicity Criteria for Adverse Events (CTCAE) v 3.0[27]. For 
the purposes of the determination of dose limiting toxicities (DLT) and maximum 
dose tolerated dose (MTD), all toxicities observed during first 2 treatment cycles 
were included. We selected 2 cycles for MTD determination as median time for 
bortezomib induced neurotoxicity is around 2 month[28]. Hematological DLT’s were 
defined as: platelets <10,000/μl on two consecutive blood draws, and/or more than 
one platelet transfusion required per week, grade 4 neutropenia (ANC < 500/μl) for 
> 7 days, neutropenia or thrombocytopenia which causes a delay of ≥ 14 days 
beyond the planned interval between treatment cycles. Patient with BM involvement 
at study entry were not eligible for evaluation of hematological DLT’s.  
 
Non-Hematological DLT’s were defined as any grade 3-4 non-hematologic toxicity 
excluding: grade 3 nausea or vomiting;  Grade 3 diarrhea lasting ≤72 hours;  grade 
3 fever or infection, with or without neutropenia; grade 3-4 stomatitis lasting ≤72 
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hours; or grade 3 transaminase elevation resolving to original eligibility criteria prior 
to next cycle of chemotherapy. Recommended dose modifications were specified in 
the study. Any patient experiencing DLT after an initial dose modification of 
irinotecan or bortezomib was removed from protocol therapy.  
Response Evaluation  
Patients who received at least two cycles of bortezomib and irinotecan were 
evaluable for response. RECIST criteria were used for response assessment in 
patients with measurable disease[29]. For patients with MIBG-avid lesions only, 
response was based upon International Neuroblastoma Response Criteria (INRC), 
examining the presence or absence of MIBG avidity in skeletal and soft-tissue sites. 
Overall response was defined using International Neuroblastoma Response Criteria 
(INRC)[30]. Survival curves were constructed using the Kaplan-Meier method[31]. 
Disease Free Survival (DFS) and Overall Survival were calculated as a secondary 
endpoint of the study. 
 
RESULTS 
Patient Characteristics: A total of 18 eligible patients with high risk NBL were 
enrolled between May 2008 to March 2012, at C.S. Mott Children’s Hospital / 
University of Michigan Medical Center, with all 18 patients eligible for toxicity 
evaluation while 17 patients were eligible for response evaluation. One patient was 
taken off protocol therapy after one cycle of therapy due to poor compliance with 
study dosing.  The patient did not experience any DLTs during study therapy. 
Demographics and clinical characteristics of the study patients are shown in Table-
  
 
This article is protected by copyright. All rights reserved. 
 
 
11 
1. Patients were enrolled on the study at the time of declaration of primary refractory 
disease (n=8) or at the time of presenting with relapsed / progressive disease 
(n=10). The majority of patients were heavily pretreated (median prior regimen=2), 
with measurable disease (n=11), bone marrow involvement (n=14), and twelve were 
status post autologous BMT. Three patients had received prior therapeutic doses of 
I131-MIBG therapy. Overall summary and clinical course of all study patients are 
described in Table-2.  
Dose Limiting Toxicities (DLT): A total of 18 patients were treated, for a total of 
142 courses of protocol therapy. Three patients were treated on DL1, 9 on DL2 and 
6 were treated on DL3 (Table-3). Two DLT’s were reported, including one at dose 
level 2 (irinotecan dose level 40mg/m2) and another at dose level-3 (irinotecan dose 
level 45mg/m2), with no DLT’s reported at dose level-1 (Table-3). The first DLT was 
a grade 4 thrombocytopenia which required > 2 platelet transfusion for 2 weeks 
during cycle 2 but without any clinical bleeding. Though the patient was eligible to 
continue study therapy (with dose reduction), the patient was electively withdrawn 
from study.  The second DLT occurred in a patient experiencing grade-3 irritability 
and inconsolable crying. The episode developed during the day 8 bortezimib dose 
during cycle 2, and continued for several hours and re-developed after the cycle 2, 
day 11 dose.  Despite multiple consolation and supportive techniques including 
diphenhydramine and lorazepam, the symptoms only resolved 12 hours after the 
last treatment dose. The patient had no history of other injury.  Follow up scans 
revealed stable disease with no disease progression in any bony sites or intracranial 
extension or evidence of any intracranial bleed. The patient exhibited otherwise 
unremarkable neurological examination including normal deep tendon reflexes, 
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sensory and motor examinations. The true cause of irritability was unclear, however 
after full evaluation to rule out other etiology, it is our clinical impression that it was 
related to neuropathic pain, a well-known toxicity of bortezomib in adults[32]. 
Irritability has not been reported as a side effect of bortezomib before and the 
patient made a full recovery from this toxicity. The family elected to pursue another 
investigational study following the 2nd cycle. Five more patients were subsequently 
enrolled on dose level-3 without DLT. Based on the TITE-CRM design described 
above, we calculated the DLT rate at each dose level given DLT information in 
Table 3. We found that posterior probabilities of DLT at Dose level-3 and 4 are 0.17 
and 0.26, respectively. Hence, dose level-3 (irinotecan 45mg/m2) was determined to 
be the MTD (the highest dose with DLT probability of no more than 0.25). Patients 
with bone marrow involvement were not eligible for heme DLT assessment. 
However, if we were to apply the heme DLT definition to all 14 patients with BM 
involvement 5/14 (36%) of patients would have met hematological DLT definition, 
including 3 patients with grade 4 neutropenia for > 7 days and 2 with 
thrombocytopenia requiring multiple transfusions in a week.  
Other Toxicities: Overall toxicity experience during the entire course of therapy is 
described in Table-4. Even though 10 patients (56%) experienced grade 3 or 4 
neutropenia, only 1 patient (6%) developed grade 3 febrile neutropenia without the 
use of granulocyte colony stimulating factor (GCSF). Three patients (18%) required 
multiple transfusions (1 PRBC and 2 platelet transfusions).  
 Even though both agents include diarrhea as a DLT in single agent clinical 
trials, only 3 (17%) reported grade 3-4 diarrhea without any DLT with very little 
moderate to severe nausea or vomiting. The incidence of peripheral neurotoxicity 
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was relatively low, with 2 patients (11%) experiencing sensory neuropathy (1 Grade-
2, 1 Grade-3).   
Anti-Tumor Activity: Two objective responses (OR) were observed out of 17 
eligible patients (12%), as defined by INRC NBL criteria[30]. One response was in 
3-year-old patient with refractory NBL with N-MYC non-amplified disease, with 
measurable soft tissue lesions in in the liver, and maxillary sinus on the right. The 
patient demonstrated a partial response by CT and MIBG scans after 6 cycles and 
maintained the response for a total of 48 cycles (Table-2). At that point the patient 
came off study to enroll in another investigational study, remaining in PR for 2 years 
post protocol therapy. A second response was seen in a 7-year-old boy with N-MYC 
non-amplified, evaluable disease in sacral bone by MIBG scan and iliac crest bone 
marrow by bone marrow evaluation. The patient had prior exposure to irinotecan 
with no objective response. However, after 2 cycles of protocol therapy he had 
complete response (CR), with complete resolution of MIBG-avidity, and clearance of 
marrow disease. He maintained in CR for a total of 44 cycles before coming off 
study to enroll on a vaccination study at an outside institution. The patient remains 
in CR 30 months post protocol therapy.  
 Four additional patients (23%) received 6 or more cycles of protocol therapy 
with minimal toxicity and prolonged stable disease (SD) (6, 6, 8 and 8 cycles 
respectively). Overall, 35% of these patients received clinical benefit from the study 
therapy, with prolonged objective responses (n=2) or prolonged disease stabilization 
(n=4). Three-year DFS and OS rates for this study cohort were 28% (± 11%) and 
44% (±12%), respectively (Figs. 1A and 1B). 
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DISCUSSION 
Bortezomib is a first in class boronic proteasome inhibitor that reversibly inhibits 
activity of the 20S proteasome but its true mechanism of action is still unknown. 
However, inhibition of NF-κB, activation of pro-apoptotic proteins like caspases and 
cleavage of DNA repair enzymes, increasing the susceptibility of cancer cells to 
classes of DNA-damaging agents are some of the proposed mechanisms[21,33,34]. 
Based on the role of NF-kB in NBL pathogenesis, our group and others explored the 
role of bortezomib in vivo and in vitro against NBL and have shown a synergy 
between bortezomib and irinotecan and other cytotoxic agents[22,35,36]  forming the 
basis of this trial. To our knowledge, this is the first clinical trial of bortezomib against 
NBL. As most of the patients with refractory / relapsed NBL have already seen very 
dose intense cytotoxic chemotherapy, we chose irinotecan given its known activity 
against neuroblastoma, favorable toxicity profile, with less myelosuppressive effects 
as compared to other cytotoxic agents. We really wanted to explore the effect of 
maximum inhibition of proteasome and its clinical effect when combined with 
escalating doses of irinotecan and because of this we elected to keep a constant 
dose of bortezomib with maximum proteasome suppression.  
The combination of bortezomib and irinotecan was very well tolerated with 
only 2 DLT’s in 18 patients and there were 6 patients who received between 6-48 
cycles of chemotherapy. Thrombocytopenia has been reported in many other single 
agent bortezomib and irinotecan studies[14,23]. In the current trial, only 4 of 18 
patients were eligible for assessment of hematologic toxicity, thus limiting our ability 
to assess thrombocytopenia. One non-hematologic DLT was irritability and 
inconsolable crying, a complaint not reported in other pediatric studies with these 
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agents. Though, the etiology of the event remains unclear, it is possible that it was a 
manifestation of neurotoxicity in a toddler. In terms of other toxicities seen in our 
trial, in general they were mild. Overall patients had no adverse impact on quality of 
life while on therapy with most continuing school or pre-school activities while on 
protocol therapy. The infectious complications were minimal with only one episode 
of febrile neutropenia without any septic episodes. Gastrointestinal side effects were 
notable for diarrhea, which was expected as both agents are known to cause 
diarrhea. However, nausea and vomiting were minimal. Surprisingly, neurotoxicity 
was also minimal which has been a major dose limiting toxicity in older adults. Prior 
exposure to cisplatin and vincristine in pre-protocol therapy for primary NBL 
treatment did not increase the incidence of neurotoxicity secondary to bortezomib in 
our study. This is similar to what has been described in adults where increasing age 
was the only predictive variable associated with neurotoxicity in response to 
bortezomib, not prior exposure to any neurotoxic agents[37].  The favorable toxicity 
profile makes this an ideal combination for using as a backbone for adding 
additional investigational agents especially in children who cannot tolerate 
temozolomide orally.  
Another novel aspect of our trial was the modified TITE-CRM phase-I study 
design. There are several potential advantages of this approach including treating 
all eligible patients[24], and keeping a trial open continuously in between doses. 
During the entire time period when this trial was open, all eligible patients who were 
interested in participating in the study were able to be enrolled on our study. This 
could be of tremendous value in improving efficiency of pediatric oncology phase-I 
clinical trials, which are known for intermittent closures and lack of available spots 
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when an eligible patient is identified. Based on extensive simulation studies we 
reported earlier, we were able to show that the TITE-CRM design was able to 1) 
identify the MTD more accurately without increasing the probability of exposing 
patients to toxic doses, and 2) treat more patients at or close to MTD dosing when 
compared more traditional designs[24],  making a very compelling case for TITE-
CRM to be a novel alternative to traditional phase-I designs for pediatric phase-I 
trials and[24]. 
We enrolled 18 patients in approximately 3 years and 10 months, which took 
much longer than we expected. Generally, the TITE-CRM design doesn’t have 
much advantage of shortening the trial duration in this situation when the patient 
recruitment is slow, but there were 4 patients enrolled within 2 weeks after the 
previously enrolled patient. It’s likely that these four patients would either have their 
entry delayed or would be treated off protocol with some other agent if the trial was 
of traditional design. Given the small sample size in phase I trials, the selected MTD 
has a large uncertainty. The model-based design using all patients’ data is likely to 
be more efficient than the rule-based designs. But the TITE-CRM design relies on 
certain assumptions (such as the dose-toxicity function and the a priori DLT 
probabilities). Although it has been shown that results are quite robust to the choice 
of dose-toxicity model[38,39], we need to carefully evaluate these assumptions for 
every trial design. 
 
In this study, we have made a conservative choice in selecting Dose level-3 
as the MTD. The DLT probability at DL3 is 17%, which is the highest dose with DLT 
probability of no more than 0.25. However, Dose level-4 has an estimated DLT 
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probability of 26%, which is only slightly larger than 25%. Because of the limited 
sample size and no data (no patient was treated) at Dose level-4, we can’t rule out 
the possibility of DL4 being the MTD. Thus, we suggest to consider both DL3 and 
DL4 in future trials. 
 
Finally, the combination of bortezomib and irinotecan showed a modest hint 
of clinical efficacy within the confines of this phase-I trial with an overall 12% OR 
rate, including in 1 patient with prior irinotecan exposure. This is similar to other 
standard therapy used in relapsed neuroblastoma [4,7]. Even though the OR were 
seen only in patients with evaluable disease, 35% of patients had prolonged SD or 
better from 6-48 courses with minimal toxicity, suggesting a very favorable long term 
toxicity profile. These findings will need to be confirmed in a larger phase-II trial to 
determine the true efficacy of this combination in refractory NBL. Going forward 
there are other treatment strategies to take advantage of these agents in efforts to 
improve the clinical response in refractory NBL. As examples, irinotecan and 
temolozomide have shown to be active in combination against refractory NBL with 
minimal toxicity and are considered an ideal backbone for the addition of novel 
biologic agents for testing. It is intriguing to consider bortezomib in such a treatment 
combination[4,7].  In addition, both irinotecan and bortezomib have shown to be 
radio-sensitizers and could be considered in combination with either therapeutic 
doses of I131-MIBG or conventional radiation therapy[40-44].  Finally, oral irinotecan 
and subcutaneous bortezomib have been shown to be equally efficacious in patient 
friendly formulations, as both agents can be delivered in an ambulatory/home 
setting[7,45].  
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Our study has several limitations: a) it is a small, single institution study b) it 
had only 4 patients without bone marrow involvement who were eligible for 
determination of hematological toxicities and so the determination of hematological 
DLT was inadequate. C) it had large inter-patient study entry time leading to a close 
to 4 year completion time and mitigated many benefits of TITE-CRM design.   
In summary, the combination of bortezomib and irinotecan was very well 
tolerated with favorable short and long term toxicity profile, and showed modest 
clinical activity. The clinical activity of this novel combination merits testing in a 
larger phase II clinical trial against refractory / relapsed neuroblastoma. 
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LEGENDS LIST:  
Fig. 1: Kaplan-Meier Survival Curve of patients with relapsed or refractory NBL (A) 
Disease free survival. (B) Overall survival 
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TABLE 1 Patient Demographics and Clinical Characteristics 
Clinical and Biological Feature Numbers 
Age, Median Years (range) 5  (1-21) 
Gender (Male/ Female) 8/ 10 
N-Myc Amplification, Yes / No/ Unknown 5/ 9/4 
Disease Status, Primary Refractory/ Relapsed 8/10 
Measurable disease, Yes / No 11/7 
Bone Marrow Involvement , Yes / No 14/4 
Prior Therapies, Median (Range) 2  (1-4) 
Prior Irinotecan Exposure (Yes/ No) 5/ 13 
Autologus BMT (Yes/ No) 12/6 
High Dose MIBG (Yes/ No) 3/15 
Patients on Dose Level 1 (Bortezomib 1.2mg/m2/Day, Irinotecan 35mg/m2/D) 3 
Patients on Dose Level 2 (Bortezomib 1.2mg/m2/Day, Irinotecan 40mg/m2/D) 9 
Patients on Dose Level 3 (Bortezomib 1.2mg/m2/Day, Irinotecan 45mg/m2/D) 6 
Number of Courses of Protocol Therapy Received, Median (Range) 2 (1-48) 
Number of patient eligible for toxicity evaluation 18 
Number of patients eligible for response evaluation 17 
Overall Responses by INRC (Percentages) 2 (12%) 
Abbreviations: BMT, Bone Marrow Transplant; MIBG, Metaiodobenzylguanidine; INRC, 
International Neuroblastoma Response Criteria 
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TABLE 2 Summary of Study Patients 
Patient  
ID 
Age 
(Yr) 
Gender 
Stage at 
Diagnosis 
N-Myc 
Amplification 
Disease 
Status 
Evaluable 
vs. 
Measurable 
Disease 
BM 
Involvement 
# of 
Previous 
Regimens 
Prior 
Irinotecan 
Exposure 
Prior 
BMT 
Prior 
MIBG 
Dose 
Level 
Total # of 
Cycles on 
Therapy 
Dose Limiting 
Toxicity (DLT) 
BestBBestBest Ov            Best 
Overall 
Response 
01 6 M IV Not amplified Relapse Evaluable Yes 3 No Yes Yes 1 6  SD 
02 17 F III Amplified 
Refractory Evaluable 
No 2 No Yes No 1 2 
 
PD 
03 21 M IV Unknown 
Refractory Measurable 
No 3 Yes Yes No 1 1 
 Not 
Evaluable 
for 
response 
04 4 M IV 
Not 
Amplified 
Refractory Measurable 
Yes 1 No Yes No 2 2 
 
PD 
05 4 M IV Amplified 
Relapse Evaluable No 
2 No Yes No 2 2 
Grade-4 
Thrombocytope
nia 
SD 
06 5 F IV Unknown 
Refractory Evaluable Yes 
2 No No No 2 2 
 
SD 
07 5 F IV Unknown 
Relapse Measurable Yes 
2 No Yes No 2 8 
 
SD 
08 2 F IV 
Not 
Amplified 
Relapse Measurable Yes 
1 No No No 2 2 
 
PD 
09 1 F IV 
Not 
Amplified 
Refractory Measurable Yes 
2 Yes Yes No 2 6 
 
SD 
010 6 M IV 
Not 
Amplified 
Relapse Measurable Yes 
1 No Yes No 2 2 
 
PD 
011 2 M 
IV Amplified Relapse Measurable 
Yes 2 No Yes No 3 
2 Grade-3 
Irritability, 
inconsolable 
crying 
PD 
012 7 M IV 
Not 
Amplified 
Refractory Evaluable Yes 
4 Yes Yes Yes 2 44 
 
CR 
013 8 F IV Amplified 
Relapse Measurable Yes 
3 Yes No No 2 2 
 
SD 
014 2 F IV Unknown 
Relapse Measurable Yes 
2 No Yes No 3 2 
 
SD 
015 3 F IV 
Not 
Amplified 
Refractory Evaluable 
No 4 No Yes No 3 48 
 
PR 
016    8 F IV Amplified Relapse Measurable Yes 1 No No No 3 3  SD 
017 5 F IV 
Not 
Amplified 
Relapse Measurable Yes 
3 Yes No Yes 3 4 
 
SD 
018 5 M IV 
Not 
Amplified 
Refractory Evaluable Yes 
1 No No No 3 8 
 
SD 
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TABLE 3 Irinotecan Dose Levels and Dose Limiting Toxicities (DLT) 
 
Dose 
Leve
l 
Bortezomi
b 
Dose 
Irinotecan 
Dose 
# of 
Patient
s 
DLT 
1 1.2 mg/m2 35 
mg/m2/da
y 
3 - 
2 1.2 mg/m2 40 
mg/m2/da
y 
9 1 
(Thrombocytopenia
) 
3 1.2 mg/m2 45 
mg/m2/da
y 
6 1 (Irritability, 
inconsolable crying) 
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TABLE 4 Highest Grade of Overall Toxicities (CTCAE 3.0)* 
Adverse Event 
None Grade 
1-2 
Grade-
3 
Grade-4 
Leukopenia 
 12 
(66%) 
3 (17%) 
3 (17%) 
Neutropenia  8 (45%) 6 (33%) 4 (22%) 
Anemia 
 17 
(94%) 
1 (6%) 
0 
Thrombocytopenia 
 13 
(72%) 
2 (11%) 
3 (17%) 
Nausea 
 17 
(94%) 
1 (6%) 
0 
Vomiting 
 17 
(94%) 
1 (6%) 
0 
Diarrhea 
3 (17%) 12 
(66%) 
2 (11%) 
1 (6%) 
Peripheral Sensory 
Neuropathy/ 
Irritability 
16 (88%) 
1 (6%) 
1 (6%) 
0 
Febrile 
Neutropenia 
17 (94%) 
 
1 (6%) 
0 
 
* Common Terminology Criteria For Adverse Event Version 3.0 
